Bespak's nasal delivery device wins firm second development deal
Under the new agreement, Bespak – a division of UK-based medical device firm Consort Medical – will develop its Unidose technology for the company, who remain unnamed.
The manufacturers also remained tight-lipped over the application of the platform, saying only that the launch is planned for 2015.
However Consort Medical CEO Jon Glenn did reveal that, for the first time, Bespak would also fill the device with packaged drug once it goes into production.
He said: “Our Cambridge innovations centre is clearly delivering a portfolio of products that leverages our competencies and our technology in adjacent market spaces.”
Early days
Though the newest developments is only the second time the Unidose system has been applied, the company now looks to further its reach within new and emerging drug delivery fields.
When Bespak launched its first nasal device development contract last month, development director Nick Higgins told in-PharmaTechnologist: “Our strategy is to become more broadly involved in the drug delivery technology market.”
And according to Jefferies equity analyst Stephan Gasteyger, the firm are looking to make more acquisitions like its 2009 takeover of The Medical Company, in which it gained the autoinjector device.
He said: “Consort Medical remains cautiously optimistic about the potential of its product pipeline and its ability to deliver double-digit earnings growth in the longer term.
“Besides improving organic growth, the company also hopes to enhance its growth profile through further acquisitions such as, for instance, the expansion into the fields of nasal and ocular drug administration.”
